Hyperfine Inc. aims to simplify monitoring of potentially dangerous adverse events associated with amyloid-targeting therapies with the launch of its Capturing ARIA Risk Equitably with Portable MR observational study. The study will evaluate the benefits of the Swoop portable brain MRI system in acquiring images needed to detect amyloid-related imaging abnormalities in Alzheimer’s patients as specified in product labeling.